REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,286.00
Bid: 12,282.00
Ask: 12,286.00
Change: 22.00 (0.18%)
Spread: 4.00 (0.033%)
Open: 12,268.00
High: 12,312.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

Mon, 25th Mar 2024 07:59

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

The US Federal Reserve left rates unmoved, but a set of projections which accompanied its decision suggested three cuts are still in the offing this year.

The Bank of England also left its benchmark rate unmoved, but there is a growing conviction it will soon cut.

BoE Governor Andrew Bailey said that interest rates are in play this year, as signs that the risk of a wage-price spiral ebb. Bailey said he is increasingly confident that inflation is heading towards the bank's target in an interview with the Financial Times.

He signalled that markets were right to expect more than one interest rate cut this year, and stressed how small the technical recession last year had been.

In early UK corporate news, AstraZeneca announced a new drug approval in the US, while Kingfisher saw its annual profit fall.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 0.2% at 7,741.12

----------

Hang Seng: marginally lower at 16,492.09

Nikkei 225: closed down 1.2% at 40,414.12

S&P/ASX 200: closed up 0.5% at 7,811.90

----------

DJIA: closed down 305.47 points, 0.8%, at 39,475.90

S&P 500: closed down 7.35 points, 0.1%, at 5,234.18

Nasdaq Composite: closed down 26.98 points, 0.2%, to 16,428.82

----------

EUR: down at USD1.0821 (USD1.0829)

GBP: down at USD1.2607 (USD1.2627)

USD: down at JPY151.24 (JPY151.46)

Gold: down at USD2,167.90 per ounce (USD2,173.50)

(Brent): up at USD85.22 a barrel (USD85.15)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

14:15 GMT UK Bank of England MPC member Catherine Mann speaks

12:25 GMT US Atlanta Fed President Raphael Bostic speaks

12:30 GMT US Chicago Fed national activity index

14:00 GMT US new home sales

14:30 GMT US Dallas Fed manufacturing business index

14:30 GMT US Federal Reserve Governor Lisa Cook speaks

----------

Prime Minister Rishi Sunak will on Monday announce GBP200 million of public investment to boost the UK's nuclear deterrent programme and its civil nuclear industry, which the government says will support 40,000 expected new jobs. The government will partner with industry leaders including BAE Systems, Rolls-Royce and EDF and Babcock to invest at least GBP763 million by 2030 in skills, jobs and education, Sunak's Downing Street office said in a press release ahead of his announcement. The investment aims to ensure that the northern England town of Barrow-in-Furness, where Sunak will make the announcement, "thrives as the home of UK nuclear submarine-building".

----------

EVE Energy is set to build the biggest gigafactory in the UK, The Sunday Times reported. The Guangdong, China-based electric vehicle batteries producer counts BMW among its customers and is the world's largest manufacturer of "Tesla-like" cylindrical car batteries. The planned factory on the outskirts of Coventry will initially see a GBP1.2 billion investment from EVE Energy for an initial 20 gigawatt capacity, with that set to expand to 60 gigawatt in following phases. EVE Energy reportedly made a multi-billion pound commitment in a letter to UK Chancellor Jeremy Hunt. The plant would create around 6,000 jobs and thousands more in the supply chain.

----------

BROKER RATING CHANGES

----------

HSBC cuts Prudential price target to 1,150 (1,745) pence - 'buy'

----------

JPMorgan places Intertek on 'positive catalyst watch'

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat some adult suffers of central nervous system disorder neuromyelitis optica spectrum. The Cambridge-based pharmaceutical company said this was based on positive results from the Champion-NMOSD phase 3 trial, in which Ultomiris met its primary endpoint. NMOSD is a rare autoimmune disease that affects the central nervous system, including the spine and optic nerves. "The diagnosed prevalence of adults with NMOSD in the US is estimated at approximately 6,000," AstraZeneca said.

----------

Kingfisher reported a decline in annual sales and profit, though the B&Q and Screwfix owner hailed a "resilient" performance in its UK and Ireland operation. Pretax profit fell 22% to GBP475 million in the financial year that ended January 31 from GBP611 million a year earlier, while sales fell 0.6% to GBP12.98 billion from GBP13.06 billion. Kingfisher maintained its total dividend for the year at 12.40 pence per share. Chief Executive Officer Thierry Garnier said: "In the UK & Ireland, B&Q, TradePoint and Screwfix each delivered resilient sales and market share growth - in particular very strong gains at Screwfix. In France, where the market has been impacted by low consumer confidence, we have made significant adjustments to the cost base and started to embed e-commerce marketplace and trade customer initiatives similar to those successfully implemented in the UK. And in Poland, where we faced strong comparatives and a tough economic backdrop, sales trends are gradually improving in line with the consumer environment." Like-for-like sales so far in the first-quarter are down 2.3% on-year, it said. It expects adjusted pretax profit for the new year in the range of GBP490 million to GBP550 million, potentially a 14% decline from what was achieved in the year just gone. Adjusted pretax profit in financial 2024 fell 25% to GBP568 million from GBP758 million.

----------

COMPANIES - FTSE 250

----------

Octopus Renewables Infrastructure Trust said its net asset value per share at its December 31 year-end stood at 90.00 pence, down 10% from 100.00p a year earlier. The NAV total return for 2023 was 2.1%, slowing from 12.4% in 2022. Pretax profit fell 82% to GBP12.7 million from GBP69.8 million. Investment income rose 6.0% to GBP42.7 million from GBP40.3 million, but its bottom line was hurt by a negative GBP23.0 million movement in fair value of investments, swinging from a gain of GBP37.6 million the prior year. The total dividend for 2023, however, increased 10% to 5.79p from 5.24p. Looking ahead, it has increased its total dividend target for 2024 by 4.0% to 6.02p, which it said was in line with UK consumer price inflation. Chair Phil Austin commented: "Despite the market challenges experienced in the investment trust sector in recent months, the fundamental driving forces behind clean energy investment are stronger than ever, and we believe that ORIT is very well placed to continue its contribution to the transition to net zero whilst ensuring an attractive level of returns for our shareholders."

----------

OTHER COMPANIES

----------

Money transfer services provider Wise announced the appointment of Delivery Hero Chief Financial Officer Emmanuel Thomassin as its next CFO on Monday, replacing Matthew Briers who had signalled his intention to step down from the role last year. Wise said Briers will now leave with immediate effect, with Thomassin joining at the start of October and Senior Group Financial Director Kingsley Kemish serving as interim CFO in the meantime. Chair David Wells commented: "We're delighted to welcome Emmanuel as our new Chief Financial Officer after an extensive global search. A seasoned CFO, leader and board member with well over a decade's experience, Emmanuel has a proven track record of scaling companies in rapidly-evolving industries - from startups to public companies. I look forward to working with him as Wise continues on its path to reshape global financial services for the 21st century."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.